If you are switching from tirzepatide to retatrutide , discuss timing with your provider as part of the transition plan
Research indicates that some users can lose up to 20% of their body weight, outperforming single-receptor medications
doi: 10.1016/j.molmet.2023.101805 80 ZhangQHuN
Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans
In the OASIS 4 trial, a Phase 3 study (large, late-stage human trials that decide whether a medication is approved), adults taking the 25 mg tablet lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on a placebo
That opinion came after the review of toxicological, nutritional, and microbiological data regarding IPE